These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25304008)

  • 1. Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint.
    Diepstraten J; Janssen EJ; Hackeng CM; van Dongen EP; Wiezer RJ; van Ramshorst B; Knibbe CA
    Eur J Clin Pharmacol; 2015 Jan; 71(1):25-34. PubMed ID: 25304008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Obesity on Anti-Xa Concentrations in Bariatric Patients.
    Schijns W; Deenen MJ; Aarts EO; Homan J; Janssen IMC; Berends FJ; Kaasjager KAH
    Obes Surg; 2018 Jul; 28(7):1997-2005. PubMed ID: 29404935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Xa Levels 4 h After Subcutaneous Administration of 5,700 IU Nadroparin Strongly Correlate with Lean Body Weight in Morbidly Obese Patients.
    Diepstraten J; Hackeng CM; van Kralingen S; Zapletal J; van Dongen EP; Wiezer RJ; van Ramshorst B; Knibbe CA
    Obes Surg; 2012 Feb; ():. PubMed ID: 22302439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients.
    van Kralingen S; Diepstraten J; Peeters MY; Deneer VH; van Ramshorst B; Wiezer RJ; van Dongen EP; Danhof M; Knibbe CA
    Clin Pharmacokinet; 2011 Nov; 50(11):739-50. PubMed ID: 21973271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
    Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels.
    Jaspers TCC; Meijer CE; Vleming LJ; Franssen CFM; Diepstraten J; Lukens MV; van den Bemt PMLA; Maat B; Khorsand N; Touw DJ; Koomen JV
    Clin Pharmacokinet; 2022 Nov; 61(11):1559-1569. PubMed ID: 36040615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis.
    Heizmann M; Baerlocher GM; Steinmann F; Horber FF; Wuillemin W
    Thromb Res; 2002 May; 106(4-5):179-81. PubMed ID: 12297122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients.
    Mast L; Peeters MYM; Söhne M; Hackeng CM; Knibbe CAJ; van den Broek MPH
    Eur J Clin Pharmacol; 2023 Nov; 79(11):1537-1547. PubMed ID: 37707559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lean body weight is the best scale for venous thromboprophylaxis algorithm in severely obese patients undergoing bariatric surgery.
    Gaborit B; Moulin PA; Bege T; Boullu S; Vincentelli C; Emungania O; Morange PE; Berdah S; Salem JE; Dutour A; Frere C
    Pharmacol Res; 2018 May; 131():211-217. PubMed ID: 29452290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.
    Romano LGR; Hunfeld NGM; Kruip MJHA; Endeman H; Preijers T
    Br J Clin Pharmacol; 2023 May; 89(5):1617-1628. PubMed ID: 36495312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels.
    Celik F; Huitema AD; Hooijberg JH; van de Laar AW; Brandjes DP; Gerdes VE
    Obes Surg; 2015 Apr; 25(4):628-34. PubMed ID: 25223871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study.
    Bai W; Zhang X; Sun S; Wang Q; Li C; Zhang X; Zhao A
    BMC Pregnancy Childbirth; 2021 Oct; 21(1):683. PubMed ID: 34620101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients.
    Smit C; Wasmann RE; Goulooze SC; Hazebroek EJ; Van Dongen EPA; Burgers DMT; Mouton JW; Brüggemann RJM; Knibbe CAJ
    Clin Pharmacokinet; 2019 Oct; 58(10):1333-1343. PubMed ID: 31016671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propofol clearance in morbidly obese children and adolescents: influence of age and body size.
    Diepstraten J; Chidambaran V; Sadhasivam S; Esslinger HR; Cox SL; Inge TH; Knibbe CA; Vinks AA
    Clin Pharmacokinet; 2012 Aug; 51(8):543-51. PubMed ID: 22690673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients.
    Lee YR; Vega JA; Duong HN; Ballew A
    Pharmacotherapy; 2015 Nov; 35(11):1007-15. PubMed ID: 26598093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fondaparinux prophylaxis on anti-factor Xa concentrations in patients with morbid obesity.
    Martinez L; Burnett A; Borrego M; Streeter JC; Townsend K; Garcia D
    Am J Health Syst Pharm; 2011 Sep; 68(18):1716-22. PubMed ID: 21880887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enoxaparin dosing after cesarean delivery in morbidly obese women.
    Overcash RT; Somers AT; LaCoursiere DY
    Obstet Gynecol; 2015 Jun; 125(6):1371-1376. PubMed ID: 26000508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
    Boneu B; Navarro C; Cambus JP; Caplain H; d'Azemar P; Necciari J; Duret JP; Gaud C; Sié P
    Thromb Haemost; 1998 Feb; 79(2):338-41. PubMed ID: 9493587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smaller nadroparin dose reductions required for patients with renal impairment: A multicenter cohort study.
    van Uden RCAE; Jaspers TCC; Meijer K; van Stralen KJ; Maat B; Khorsand N; van Onzenoort HAW; Swart EL; Huls HJ; Mathôt RAA; Lukens MV; van den Bemt PMLA; Becker ML
    Thromb Res; 2024 Apr; 236():4-13. PubMed ID: 38377636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis.
    Brill MJ; Houwink AP; Schmidt S; Van Dongen EP; Hazebroek EJ; van Ramshorst B; Deneer VH; Mouton JW; Knibbe CA
    J Antimicrob Chemother; 2014 Mar; 69(3):715-23. PubMed ID: 24214905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.